Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-391 (Atorvastatin + Ezetimibe) in Primary Hypercholesterolemia
NCT02451098Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin + ezetimibe in hypercholesterolemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Change from baseline in Low-Density Lipoprotein Cholesterol at 8 weeks. Started Mar 2015; status: completed.
02
Drugs
atorvastatin + ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02451098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451098.